{"url_path":"/sec/fth/8-k/2026-05-15/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-225323-index.html","accession_number":"0001193125-26-225323","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-225323-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":130,"has_tables":true,"body_markdown":"Item 2.02\n\nResults of Operations and Financial Condition.\n\nOn May 15, 2026, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1.\n\nThe information in this Item 2.02 and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing."}